Literature DB >> 21465254

Whole-body hybrid PET/MRI: ready for clinical use?

Osman Ratib, Thomas Beyer.   

Abstract

Mesh:

Year:  2011        PMID: 21465254     DOI: 10.1007/s00259-011-1790-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  21 in total

1.  A study of artefacts in simultaneous PET and MR imaging using a prototype MR compatible PET scanner.

Authors:  R B Slates; K Farahani; Y Shao; P K Marsden; J Taylor; P E Summers; S Williams; J Beech; S R Cherry
Journal:  Phys Med Biol       Date:  1999-08       Impact factor: 3.609

Review 2.  Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.

Authors:  Johannes Czernin; Martin Allen-Auerbach; Heinrich R Schelbert
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 3.  Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques.

Authors:  Matthias Hofmann; Bernd Pichler; Bernhard Schölkopf; Thomas Beyer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 4.  Combined PET/MRI: a new dimension in whole-body oncology imaging?

Authors:  Gerald Antoch; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 5.  Dual-modality PET/CT instrumentation-today and tomorrow.

Authors:  Markus Nowak Lonsdale; Thomas Beyer
Journal:  Eur J Radiol       Date:  2010-01-21       Impact factor: 3.528

Review 6.  Focus on time-of-flight PET: the benefits of improved time resolution.

Authors:  Maurizio Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-13       Impact factor: 9.236

7.  Simultaneous PET and MR imaging.

Authors:  Y Shao; S R Cherry; K Farahani; K Meadors; S Siegel; R W Silverman; P K Marsden
Journal:  Phys Med Biol       Date:  1997-10       Impact factor: 3.609

8.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

Authors:  Gerald Antoch; Nina Saoudi; Hilmar Kuehl; Gerlinde Dahmen; Stefan P Mueller; Thomas Beyer; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

9.  Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.

Authors:  Wenfeng Yang; Zheng Fu; Jinming Yu; Shuanghu Yuan; Baijiang Zhang; Daotang Li; Ligang Xing; Dongbo Zhao; Dianbin Mu; Xiaorong Sun; Yufang Fang; Yong Huang; Yong Huange; Wanhu Li
Journal:  Lung Cancer       Date:  2008-01-04       Impact factor: 5.705

Review 10.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more
  19 in total

Review 1.  Clinical and research applications of simultaneous positron emission tomography and MRI.

Authors:  F Fraioli; S Punwani
Journal:  Br J Radiol       Date:  2013-11-14       Impact factor: 3.039

2.  Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen.

Authors:  Felix P Kuhn; David W Crook; Caecilia E Mader; Philippe Appenzeller; G K von Schulthess; Daniel T Schmid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-07       Impact factor: 9.236

3.  Approaches for the optimization of MR protocols in clinical hybrid PET/MRI studies.

Authors:  Maria-Isabel Vargas; Minerva Becker; Valentina Garibotto; Susanne Heinzer; Pierre Loubeyre; Joanna Gariani; Karl Lovblad; Jean-Paul Vallée; Osman Ratib
Journal:  MAGMA       Date:  2012-09-25       Impact factor: 2.310

Review 4.  Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective.

Authors:  Antonis Kalemis; Bénédicte M A Delattre; Susanne Heinzer
Journal:  MAGMA       Date:  2012-08-07       Impact factor: 2.310

Review 5.  PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine.

Authors:  Patrick Veit-Haibach; Felix Pierre Kuhn; Florian Wiesinger; Gaspar Delso; Gustav von Schulthess
Journal:  MAGMA       Date:  2012-10-09       Impact factor: 2.310

6.  Incorporating MRI structural information into bioluminescence tomography: system, heterogeneous reconstruction and in vivo quantification.

Authors:  Jun Zhang; Duofang Chen; Jimin Liang; Huadan Xue; Jing Lei; Qin Wang; Dongmei Chen; Ming Meng; Zhengyu Jin; Jie Tian
Journal:  Biomed Opt Express       Date:  2014-05-20       Impact factor: 3.732

Review 7.  Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting.

Authors:  Bernhard Sattler; Thies Jochimsen; Henryk Barthel; Kerstin Sommerfeld; Patrick Stumpp; Karl-Titus Hoffmann; Matthias Gutberlet; Arno Villringer; Thomas Kahn; Osama Sabri
Journal:  MAGMA       Date:  2012-10-09       Impact factor: 2.310

8.  Effect of MR contrast agents on quantitative accuracy of PET in combined whole-body PET/MR imaging.

Authors:  Cristina Lois; Ilja Bezrukov; Holger Schmidt; Nina Schwenzer; Matthias K Werner; Jürgen Kupferschläger; Thomas Beyer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-14       Impact factor: 9.236

Review 9.  Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Authors:  M Picchio; P Mapelli; V Panebianco; P Castellucci; E Incerti; A Briganti; G Gandaglia; M Kirienko; F Barchetti; C Nanni; F Montorsi; L Gianolli; S Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-17       Impact factor: 9.236

10.  Diagnostic value of combined ¹⁸F-FDG PET/MRI for staging and restaging in paediatric oncology.

Authors:  Thomas Pfluger; Henriette I Melzer; Wolfgang P Mueller; Eva Coppenrath; Peter Bartenstein; Michael H Albert; Irene Schmid
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.